JULIA BOOTHE: Open Payments
NPI 1255397824 · REFORM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,821 in 98 payments from 21 companies in 2025. Trend: 2023 $1,597 · 2024 $1,646 · 2025 $1,821
Food & beverage: $1,821
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $305 |
| Vanda Pharmaceuticals Inc. | 16 | $300 |
| Otsuka America Pharmaceutical, Inc. | 11 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $125 |
| Novo Nordisk Inc | 6 | $116 |
| Ardelyx, Inc. | 5 | $108 |
| Novartis Pharmaceuticals Corporation | 4 | $102 |
| Neurocrine BioSciences, Inc. | 5 | $92 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $92 |
| GlaxoSmithKline, LLC. | 5 | $82 |
Products named: FANAPT, REXULTI, VRAYLAR, CAPLYTA, IBSRELA, LEQVIO, INGREZZA, Kerendia.
Industry payments across AL — which companies pay providers there.
